- Price
- $57.67
- Day
- -2.27%
- Mkt Cap
- $14.50B
- 52W Range
- $33.76 – $59.72
- Volume
- 2.37M
- Beta
- 0.42
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
Exelixis is downgraded from "Strong Buy" to "Hold" due to lowered 2026 revenue guidance and mixed clinical trial outcomes. Zanzalintinib + TECENTRIQ achieved overall survival benefit in mCRC, but missed the non-liver metastases subgroup endpoint; FDA PDUFA date set for December 3, 2026. Q2 2026 revenues rose to $628.7M, but future sales growth is uncertain and full-year guidance was cut to $2.500–$2.550B.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 8:00 a.m. PT on Tuesday, September 8 in Boston. Citi 2026 Biopharma Back to School Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Wednesday, September 9 in New York City. Morgan.